CardioComm Solutions to be an integral part of Europtima’s strategic initiative to introduce state-of-the-art medical solutions overseas

TORONTO, ONTARIO – CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) a global medical provider of consumer heart monitoring and medical electrocardiogram (“ECG”) software solutions, today confirmed that is has signed a marketing and sales agreement with UAE-based Europtima Medical Solutions FZ, LLC (“EMS”), a company dedicated to provide medical technology, hardware and software solutions to hospitals, private clinics and other medical facilities in several middle east countries as well as Africa and Europe.

With offices globally, EMS leverages their 25 years of experience to find and introduce innovative medical solutions and to provide complete, state-of-the-art, high quality medical end-to-end solutions to their customers in the medical industry. Armed with great relationships with R&D institutes internationally, EMS has established strategic alliances with inventors and innovators worldwide. “We at EMS scout and identify breakthrough technologies that are game changers and disrupting the medical care delivery status quo, then we bring them to our established networks”, says Ray Kattar CEO of EMS. The CardioComm Solutions Agreement is EMS’ most recent partnership undertaking.

The Marketing and Sales Agreement was executed in July 2015 however the collaborative kick off occurred in October with EMS introducing and launching preventative ECG monitoring solutions involving the HeartCheck™ PEN and GEMS™ WIN technologies. There is an emphasis on reducing the effects of Atrial Fibrillation (“AF”) with clients within countries under the Gulf Cooperation Council (“GCC”), as well as the rest of the Middle East and North Africa (“MENA”) region including Jordan, Iran, Palestine, Lebanon, Morocco, Egypt and Libya.

CardioComm Solutions’ technologies will form an integral part of EMS’ product portfolio and strategy and the two companies are working to develop a roadmap to place the Company’s ECG management technologies and monitoring services as competitively priced, high-value solutions to EMS customers to ensuring their growth, profitability and continuity of medical excellence. The target customers are hospital-based electrophysiology (“EP”) labs and cardiac centers, cardiology and internal medicine private clinics and retail chain pharmacies.

EMS has trained their sales teams on the CardioComm Solutions offerings, as well as developed a comprehensive go-to-market plan for building awareness in the region through participation in key conferences, symposiums, product demos and other strategic marketing activities. EMS has also confirmed that several pilot and proof-of-concept projects are also underway.

Appropriate medical device certifications, such as FDA clearances, are required for medical solutions to be sold within the GCC and MENA regions. CardioComm Solutions’ GEMS™ WIN ECG management solutions and the cost effect HeartCheck™ ECG device, GEMS™ Home and SMART Monitoring ECG services will provide healthcare organizations within these regions to implement arrhythmia screening and treatment procedure in a standardized fashion and similar to those applied within North America.

The Company plans to continue with a set of structured campaigns to expand customer and investor awareness of its consumer and hospital biotechnology, health and wellness and heart monitoring innovations across a broader cross-section. To learn more about CardioComm Solutions’ consumer HeartCheck™ ECG products and their hospital-based ambulatory cardiac arrhythmia technologies GEMS™ WIN, please see the Company’s websites at www.theheartcheck.com and www.cardiocommsolutions.com.